Zobrazeno 1 - 10
of 357
pro vyhledávání: '"Finn, Sellebjerg"'
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Human T cells expressing CD20 play an important role in the defense against virus and cancer and are central in the pathogenesis of both malignancies and various autoimmune disorders. Therapeutic modulation of CD20+ T cells and the CD20 expression le
Externí odkaz:
https://doaj.org/article/f15af0fca5fd4b6bbb3b38712b1bab5e
Autor:
Sahla El Mahdaoui, Marie Mathilde Hansen, Marina Rode von Essen, Victoria Hyslop Hvalkof, Rikke Holm Hansen, Mie Reith Mahler, Poul Jennum, Finn Sellebjerg, Jeppe Romme Christensen
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 11, Iss 4, Pp 926-937 (2024)
Abstract Objectives B cells are important in the pathogenesis of multiple sclerosis. It is yet unknown which subsets may be involved, but atypical B cells have been proposed as mediators of autoimmunity. In this study, we investigated differences in
Externí odkaz:
https://doaj.org/article/c759b7d0073346f1b5d647c83a70b1ed
Autor:
Helen Dawes, Jesper Lundbye-Jensen, Tobias Sejbaek, Viktoria Papp, Ulrik Dalgas, Finn Sellebjerg, Lars G Hvid, Laurits Taul-Madsen, Jeppe Romme Christensen, Rikke Ratzer, Kristina Bacher Svendsen, Helene Højsgaard Chow
Publikováno v:
BMJ Open, Vol 14, Iss 8 (2024)
Introduction Multiple sclerosis (MS) causes a broad range of symptoms, with physical function being one of the most disabling consequences according to patients themselves. Exercise effectively improves lower extremity physical function. Nonetheless,
Externí odkaz:
https://doaj.org/article/9f41ba5b5dbf4cca938e747885bc466b
Autor:
Rikke Holm Hansen, Marina Rode von Essen, Mie Reith Mahler, Stefan Cobanovic, Finn Sellebjerg
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionCladribine tablet therapy is an efficacious treatment for multiple sclerosis (MS). Recently, we showed that one year after the initiation of cladribine treatment, T and B cell crosstalk was impaired, reducing potentially pathogenic effect
Externí odkaz:
https://doaj.org/article/4f1de8c837d446979e2354b430ebadbc
Autor:
Julie Schjødtz Hansen, Fernando Boix, Jørgen Bo Hasselstrøm, Lambert Kristiansen Sørensen, Mads Kjolby, Stefan Gustavsen, Rikke Middelhede Hansen, Thor Petersen, Finn Sellebjerg, Helge Kasch, Peter Vestergaard Rasmussen, Nanna Brix Finnerup, Eva Aggerholm Sædder, Kristina Bacher Svendsen
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 1, Pp n/a-n/a (2024)
Abstract Information on the pharmacokinetics (PK) and pharmacodynamics (PD) of orally administered cannabis‐based medicine (CBM) in capsule formulation in patient populations is sparse. In this exploratory study, we aimed to evaluate the PK and PD
Externí odkaz:
https://doaj.org/article/10dc6ec2cd884a1fa87cd0080298e519
Autor:
Tim Spelman, Melinda Magyari, Helmut Butzkueven, Anneke Van Der Walt, Sandra Vukusic, Maria Trojano, Pietro Iaffaldano, Dana Horáková, Jirí Drahota, Fabio Pellegrini, Robert Hyde, Pierre Duquette, Jeannette Lechner-Scott, Seyed Aidin Sajedi, Patrice Lalive, Vahid Shaygannejad, Serkan Ozakbas, Sara Eichau, Raed Alroughani, Murat Terzi, Marc Girard, Tomas Kalincik, Francois Grand'Maison, Olga Skibina, Samia J. Khoury, Bassem Yamout, Maria Jose Sa, Oliver Gerlach, Yolanda Blanco, Rana Karabudak, Celia Oreja-Guevara, Ayse Altintas, Stella Hughes, Pamela McCombe, Radek Ampapa, Koen de Gans, Chris McGuigan, Aysun Soysal, Julie Prevost, Nevin John, Jihad Inshasi, Leszek Stawiarz, Ali Manouchehrinia, Lars Forsberg, Finn Sellebjerg, Anna Glaser, Luigi Pontieri, Hanna Joensen, Peter Vestergaard Rasmussen, Tobias Sejbaek, Mai Bang Poulsen, Jeppe Romme Christensen, Matthias Kant, Morten Stilund, Henrik Mathiesen, Jan Hillert, The Big MS Data Network: a collaboration of the Czech MS Registry, the Danish MS Registry, Italian MS Registry, Swedish MS Registry, MSBase Study Group, and OFSEP
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundTreatment switching is a common challenge and opportunity in real-world clinical practice. Increasing diversity in disease-modifying treatments (DMTs) has generated interest in the identification of reliable and robust predictors of treatme
Externí odkaz:
https://doaj.org/article/3d52ca1fdc794fa48cba7a9cc328885d
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
IntroductionMultiple sclerosis (MS) is a neurodegenerative disease accumulating disabilities over time. However, the mean age of individuals with MS is increasing, consequently elevating their risk of developing comorbidities. Comorbidities' impact o
Externí odkaz:
https://doaj.org/article/eddb7a01098243e495e471175d97404f
Autor:
Anja Hviid Simonsen, Helena Sophia Gleerup, Christian Sandøe Musaeus, Finn Sellebjerg, Malene Bredahl Hansen, Helle Bach Søndergaard, Gunhild Waldemar, Steen Gregers Hasselbalch
Publikováno v:
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 15, Iss 4, Pp n/a-n/a (2023)
Abstract INTRODUCTION Early and accurate diagnosis of neurocognitive disorders including neurodegenerative dementia remains challenging. This study explores the impact of biological factors on serum neurofilament light chain (NfL) levels and clinical
Externí odkaz:
https://doaj.org/article/8e56847c49b9434987ac36ba603dad50
Autor:
Florence Thirion, Finn Sellebjerg, Yong Fan, Liwei Lyu, Tue H. Hansen, Nicolas Pons, Florence Levenez, Benoit Quinquis, Evelina Stankevic, Helle B. Søndergaard, Thomas M. Dantoft, Casper S. Poulsen, Sofia K. Forslund, Henrik Vestergaard, Torben Hansen, Susanne Brix, Annette Oturai, Per Soelberg Sørensen, Stanislav D. Ehrlich, Oluf Pedersen
Publikováno v:
Genome Medicine, Vol 15, Iss 1, Pp 1-17 (2023)
Abstract Background Multiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults. It is hypothesized that a disrupted bacterial and viral gut microbiota is a part
Externí odkaz:
https://doaj.org/article/92667d91f9624abab5f3c3539b861d21
Autor:
Marina Rode von Essen, Helene Højsgaard Chow, Rikke Holm Hansen, Sophie Buhelt, Finn Sellebjerg
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Alemtuzumab is a monoclonal antibody targeting CD52 on the surface of immune cells, approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). The purpose of this study was to analyze the repopulation of peripheral lymphocyte
Externí odkaz:
https://doaj.org/article/0bc8462f76ff4996874bef66bfea3bf7